{"id":"blood-specimen","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108414","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Blood specimen refers to a biological sample collected for laboratory analysis and diagnostic testing. It is not a pharmaceutical agent and does not have a therapeutic mechanism of action. This appears to be a mislabeling or data entry error in a pharmaceutical database.","oneSentence":"Blood specimen is a diagnostic sample collection, not a drug with a pharmacological mechanism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:41:17.919Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06735599","phase":"NA","title":"Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure","status":"RECRUITING","sponsor":"Georgia State University","startDate":"2024-09-17","conditions":"Hypertension (Without Type 2 Diabetes Mellitus), High Blood Pressure, Male","enrollment":40},{"nctId":"NCT00923221","phase":"","title":"Collection of Blood From Patients With Prostate Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-02-28","conditions":"Cancer Of Prostate, Prostate Cancer, Prostatic Neoplasms","enrollment":1000},{"nctId":"NCT07497412","phase":"","title":"The Effect of Continuous Positive Airway Therapy on the Blood Pressure in Sleepy vs Non-sleepy Patients With Obstructive Sleep Apnea","status":"ACTIVE_NOT_RECRUITING","sponsor":"King's College London","startDate":"2026-01-01","conditions":"Obstructive Sleep Apnea","enrollment":10000},{"nctId":"NCT03654105","phase":"PHASE2","title":"Screening and Multiple Intervention on Lung Epidemics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2019-07-23","conditions":"Inflammation, Smoking Cessation, Diet Modification","enrollment":2000},{"nctId":"NCT05168462","phase":"PHASE4","title":"Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2022-10-01","conditions":"Cardiogenic Shock, Myocardial Infarction","enrollment":776},{"nctId":"NCT07494279","phase":"NA","title":"Efficacy of Nigella Sativa (Nisatol®) in Women With Borderline Blood Pressure Values or a Non-Dipper Blood Pressure Phenotype","status":"NOT_YET_RECRUITING","sponsor":"Liaquat University of Medical & Health Sciences","startDate":"2026-03-30","conditions":"Prehypertension, Hypertension","enrollment":106},{"nctId":"NCT04929028","phase":"PHASE2","title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-09","conditions":"AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT00004577","phase":"","title":"Study of New Magnetic Resonance Imaging Methods of the Brain","status":"RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2000-07-01","conditions":"Healthy Volunteer, Magnetic Resonance Imaging, Healthy","enrollment":1100},{"nctId":"NCT03907475","phase":"PHASE2","title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":115},{"nctId":"NCT04704661","phase":"PHASE1","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-09","conditions":"Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma","enrollment":51},{"nctId":"NCT03055013","phase":"PHASE3","title":"Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-28","conditions":"Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v7","enrollment":819},{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT07498166","phase":"NA","title":"Project Tendura: The Impact of Blood Flow Restriction Resistance Training (BFR-RT) in Patients With Achilles Tendon Rupture (ATR) Repair","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-02-01","conditions":"Achilles Tendon Rupture, Blood Flow Restriction Therapy, Achilles Tendon Repairs/Reconstructions","enrollment":75},{"nctId":"NCT05600894","phase":"PHASE2","title":"Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-06-27","conditions":"Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts","enrollment":132},{"nctId":"NCT01167712","phase":"PHASE3","title":"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09-27","conditions":"Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma","enrollment":692},{"nctId":"NCT05687123","phase":"PHASE1","title":"Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-14","conditions":"Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, Stage III Pancreatic Neuroendocrine Tumor AJCC v8","enrollment":24},{"nctId":"NCT06385483","phase":"PHASE2","title":"Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-28","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":19},{"nctId":"NCT07156227","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-22","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma","enrollment":39},{"nctId":"NCT06514261","phase":"PHASE1","title":"Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-12-18","conditions":"Acute Myeloid Leukemia","enrollment":45},{"nctId":"NCT01896999","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03-07","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":146},{"nctId":"NCT03188900","phase":"","title":"Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-12","conditions":"Preeclampsia","enrollment":236},{"nctId":"NCT02436707","phase":"PHASE2","title":"Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-10-27","conditions":"Lymphoma","enrollment":129},{"nctId":"NCT03816345","phase":"PHASE1","title":"Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Autoimmune Disease, Crohn Disease, Dermatomyositis","enrollment":300},{"nctId":"NCT06439836","phase":"PHASE1","title":"Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-05","conditions":"Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":27},{"nctId":"NCT00007150","phase":"PHASE2","title":"Treatment of Hemochromatosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2001-01-01","conditions":"Hemochromatosis","enrollment":622},{"nctId":"NCT04550494","phase":"PHASE2","title":"Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-26","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma","enrollment":36},{"nctId":"NCT02579967","phase":"PHASE2","title":"Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-19","conditions":"Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, Immune System Diseases","enrollment":354},{"nctId":"NCT04665739","phase":"PHASE2","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-03","conditions":"Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm","enrollment":70},{"nctId":"NCT05377424","phase":"PHASE1, PHASE2","title":"Adenosine 2A Receptor Antagonism and AIH in ALS","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2022-06-21","conditions":"ALS","enrollment":40},{"nctId":"NCT02531880","phase":"PHASE1","title":"Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy","status":"RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2024-11-19","conditions":"Epilepsy","enrollment":40},{"nctId":"NCT06498635","phase":"PHASE3","title":"Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-04-01","conditions":"Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":306},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT04387656","phase":"","title":"NCI COVID-19 in Cancer Patients, NCCAPS Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-05","conditions":"COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm","enrollment":1877},{"nctId":"NCT05112601","phase":"PHASE2","title":"Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-02","conditions":"Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma","enrollment":81},{"nctId":"NCT07061951","phase":"PHASE2","title":"Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-09-08","conditions":"Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia","enrollment":20},{"nctId":"NCT04317105","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-17","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":54},{"nctId":"NCT04040634","phase":"NA","title":"Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-08-08","conditions":"Diabetes Mellitus, High Blood Pressure, Cardiovascular Diseases","enrollment":9476},{"nctId":"NCT02839707","phase":"PHASE2, PHASE3","title":"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-23","conditions":"Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma","enrollment":444},{"nctId":"NCT07061964","phase":"PHASE2","title":"Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-25","conditions":"Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8","enrollment":111},{"nctId":"NCT04166409","phase":"PHASE3","title":"A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-01-31","conditions":"Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma","enrollment":170},{"nctId":"NCT01553214","phase":"PHASE4","title":"Improving White Blood Cell Collection From Healthy Donors","status":"RECRUITING","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2012-12-31","conditions":"Allogeneic Granulocyte Donation","enrollment":1000},{"nctId":"NCT06203600","phase":"PHASE2, PHASE3","title":"Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-24","conditions":"Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma","enrollment":224},{"nctId":"NCT04524871","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-01","conditions":"Advanced Liver Cancers","enrollment":518},{"nctId":"NCT07494435","phase":"PHASE2","title":"Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Haichang Biotech Co., Ltd.","startDate":"2026-06-01","conditions":"Hepato Cellular Carcinoma (HCC), Renal Cell Cancer","enrollment":230},{"nctId":"NCT03686124","phase":"PHASE1, PHASE2","title":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2019-05-14","conditions":"Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult","enrollment":375},{"nctId":"NCT04284787","phase":"PHASE2","title":"BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-16","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":60},{"nctId":"NCT04052555","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-24","conditions":"Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma, Localized Breast Carcinoma","enrollment":42},{"nctId":"NCT04164082","phase":"PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-03-18","conditions":"Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8","enrollment":161},{"nctId":"NCT07024784","phase":"PHASE2","title":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-07-30","conditions":"Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer","enrollment":377},{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290},{"nctId":"NCT01468896","phase":"PHASE1, PHASE2","title":"Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-10-26","conditions":"Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma","enrollment":23},{"nctId":"NCT04310020","phase":"PHASE2","title":"Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-13","conditions":"Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":47},{"nctId":"NCT06980038","phase":"PHASE2","title":"Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-21","conditions":"Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma","enrollment":44},{"nctId":"NCT03811015","phase":"PHASE3","title":"Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-16","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":636},{"nctId":"NCT05773274","phase":"PHASE2","title":"Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-12","conditions":"Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1","enrollment":100},{"nctId":"NCT06126276","phase":"PHASE2","title":"Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-07","conditions":"Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm","enrollment":70},{"nctId":"NCT07498660","phase":"NA","title":"PRP Injection Into the Sacroiliac Joint After Ipsilateral THA: Effects on Early Recovery and Function (SIJ-THA Randomized Trial)","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2026-04-01","conditions":"Osteoarthitis, Sacro Iliac Joint Pain, Hip Arthroplasty, Total","enrollment":60},{"nctId":"NCT03854474","phase":"PHASE1, PHASE2","title":"Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-11-18","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8","enrollment":30},{"nctId":"NCT06400238","phase":"PHASE2","title":"Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-10-15","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":35},{"nctId":"NCT04585958","phase":"PHASE1","title":"Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-21","conditions":"Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm","enrollment":55},{"nctId":"NCT06661915","phase":"PHASE2","title":"A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-08-14","conditions":"Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm, Essential Thrombocythemia","enrollment":62},{"nctId":"NCT04090398","phase":"PHASE2","title":"Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-04","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone","enrollment":70},{"nctId":"NCT06965114","phase":"PHASE1, PHASE2","title":"Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-27","conditions":"Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia","enrollment":84},{"nctId":"NCT05372640","phase":"PHASE1","title":"Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma","enrollment":45},{"nctId":"NCT05941520","phase":"PHASE2","title":"Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-23","conditions":"Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ","enrollment":80},{"nctId":"NCT06311227","phase":"PHASE2","title":"Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-12-16","conditions":"Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant","enrollment":20},{"nctId":"NCT07147231","phase":"PHASE1, PHASE2","title":"Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461) in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-31","conditions":"Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8","enrollment":86},{"nctId":"NCT02496208","phase":"PHASE1","title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-07-22","conditions":"Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma","enrollment":152},{"nctId":"NCT06498648","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-18","conditions":"Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma","enrollment":74},{"nctId":"NCT06948448","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2025-11-18","conditions":"Colorectal Cancer","enrollment":144},{"nctId":"NCT01089101","phase":"PHASE1, PHASE2","title":"Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-07-07","conditions":"Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Neurofibromatosis Type 1","enrollment":217},{"nctId":"NCT07030166","phase":"","title":"A Machine Learning Prediction Model for Postoperative Acute Kidney Injury in Non-Cardiac Surgery Patients","status":"RECRUITING","sponsor":"Lanyue Zhu","startDate":"2025-07-01","conditions":"Kidney Injury, Acute","enrollment":10000},{"nctId":"NCT03741023","phase":"NA","title":"Disorders of the Acute Phase Response Following Trauma and Invasive Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2019-12-12","conditions":"Acute Phase Response","enrollment":320},{"nctId":"NCT07324096","phase":"NA","title":"A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-03-24","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":100},{"nctId":"NCT06982222","phase":"PHASE1","title":"Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-31","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma","enrollment":24},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT05111561","phase":"PHASE1","title":"Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-02","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm","enrollment":42},{"nctId":"NCT05136196","phase":"PHASE2","title":"BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-06","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":150},{"nctId":"NCT03620019","phase":"PHASE2","title":"Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-09-10","conditions":"Melanoma Stage Iii, Melanoma Stage Iv, Melanoma","enrollment":25},{"nctId":"NCT02834013","phase":"PHASE2","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-30","conditions":"Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma","enrollment":818},{"nctId":"NCT07496008","phase":"","title":"Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-03-25","conditions":"Isavuconazole, Invasion Pulmonary Mycosis","enrollment":150},{"nctId":"NCT03698019","phase":"PHASE2","title":"A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-02-15","conditions":"Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":313},{"nctId":"NCT03191149","phase":"PHASE2","title":"Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-04-25","conditions":"Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7","enrollment":46},{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT06869447","phase":"NA","title":"New York Better Breathing Study","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-15","conditions":"Localized Lung Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8","enrollment":100},{"nctId":"NCT07495267","phase":"NA","title":"Nutritional Ketosis Marfan","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-03-13","conditions":"Marfan Syndrome, Aortic Dissection","enrollment":15},{"nctId":"NCT05168787","phase":"","title":"Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2020-08-13","conditions":"Heart Failure","enrollment":6558},{"nctId":"NCT00658814","phase":"PHASE2","title":"Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-12-01","conditions":"Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia","enrollment":133},{"nctId":"NCT02728635","phase":"NA","title":"Epigenetic Regulation of Human Adipose Tissue Distribution","status":"ACTIVE_NOT_RECRUITING","sponsor":"AdventHealth Translational Research Institute","startDate":"2016-07","conditions":"Obesity","enrollment":27},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT07247110","phase":"PHASE1","title":"A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-16","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT01143454","phase":"","title":"Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2010-07-21","conditions":"Metabolic Disease, Obesity, Li-Fraumeni Syndrome","enrollment":5000},{"nctId":"NCT02595931","phase":"PHASE1","title":"M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-07-22","conditions":"Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm","enrollment":66},{"nctId":"NCT04840589","phase":"PHASE1","title":"Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-02","conditions":"Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma","enrollment":66},{"nctId":"NCT01989585","phase":"PHASE1, PHASE2","title":"Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03-24","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm","enrollment":75},{"nctId":"NCT03375320","phase":"PHASE3","title":"Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-10-26","conditions":"Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm","enrollment":298},{"nctId":"NCT06050252","phase":"PHASE2","title":"Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-10","conditions":"Resectable Intrahepatic Cholangiocarcinoma","enrollment":27},{"nctId":"NCT07495150","phase":"NA","title":"Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis","status":"NOT_YET_RECRUITING","sponsor":"yilong Wang","startDate":"2026-04-01","conditions":"Blood-Brain Barrier, Bacterial Meningitis","enrollment":86},{"nctId":"NCT06317649","phase":"PHASE2","title":"Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-27","conditions":"Acute Myeloid Leukemia","enrollment":147},{"nctId":"NCT05691478","phase":"PHASE2, PHASE3","title":"A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-03","conditions":"High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma","enrollment":1122}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1336,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"blood specimen","genericName":"blood specimen","companyName":"Centre Hospitalier Universitaire de Saint Etienne","companyId":"centre-hospitalier-universitaire-de-saint-etienne","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}